additional

Subcutaneous RYBREVANT(amivantamab) delivers promising 45 percent overall response rate with median duration of response of 7.2 months in recurrent or metastatic head and neck cancer

Responses were rapid and durable, and tumour shrinkage was observed in 82 percent of patients1 New findings from this investigational…

2 weeks ago

IMG Expands iTravelInsured Choice with New Add-Ons and Specialized Plans

INDIANAPOLIS, Oct. 14, 2025 /PRNewswire/ -- IMG (International Medical Group) has announced new optional coverage add-ons to its most popular…

3 weeks ago

Market Alert: AlphaTON Capital Continues in Growth Mode and Purchases an additional 300,000 TON

Dover, DE, Oct. 12, 2025 (GLOBE NEWSWIRE) -- AlphaTON Capital Corp. (Nasdaq: ATON) stated that during the market conditions of…

3 weeks ago

Automobili Lamborghini strengthens its Board of Management

New appointments to support the future strategy of the Sant’Agata Bolognese companySant’Agata Bolognese, 9th October 2025 – Automobili Lamborghini announces…

4 weeks ago

Kia PV5 Redefines Mobility ThroughCustomerCentric Modular Design

Built to meet customers’ evolving needs, PV5 is first dedicated model in Kia’s Platform Beyond Vehicle (PBV) business strategy Embodies…

4 weeks ago

Massive Gaming Launches Tablet-Based Slot Titles for On-Premises Environment

Five MVG titles debut, with additional games to follow in phased rollout SYDNEY, Oct. 1, 2025 /PRNewswire/ -- Massive Gaming…

1 month ago

Kia advances EV Mobility experience with new Plug and Charge Technology

Kia Plug & Charge technology for seamless EV charging at compatible stations is coming soon1Available on eligible Kia 2026 EV9…

1 month ago

Factor2 Energy Raises US$9.1M to Unlock Scalable Geothermal Power from Geologically Stored CO

DUISBURG, Germany, Sept. 19, 2025 /PRNewswire/ -- Factor2 Energy, a German (Duisburg) company with a novel approach to geothermal energy, today…

2 months ago

Skyhawk Therapeutics Announces Positive First Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington’s Disease

SKY-0515 achieves dose-dependent reductions of mutant huntingtin (mHTT) protein, with 62% lowering at Day 84 on the 9mg daily oral…

2 months ago

Chiesi Global Rare Diseases Highlights Continued Commitment to Rare Disease Community at the International Congress of Inborn Errors of Metabolism (ICIEM) 2025

September 09, 2025 11:00 ET  | Source: Chiesi Global Rare Diseases Results presented focus on clinical insights on Fabry disease…

2 months ago